Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blasts

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Sep 2018: Trial registered, NCT03674411
  2. 2 Jan 2019: Trial started, NCT03674411

The trials

NCT03674411: Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

State
Under way
Phase
Phase 2
People
22 taking part
Started
2 Jan 2019
Primary completion
23 Jun 2020
Arms
FLU, CY, TBI + MGTA-456 infusion
Results
Posted on the registry
  1. 17 Sep 2018: Trial registered
  2. 2 Jan 2019: Trial started
  3. 30 Jan 2024: Trial results posted

Posted results

The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.

Percentage of Participants With Neutrophil Recover

Primary outcome · Number, Percentage of participants · Day 14

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1631 (95% Confidence Interval 14 to 60)
BU,FLU, MEL + MGTA-456 Infusion250 (95% Confidence Interval 9 to 99)

Number of Days Alive Without Hospitalization

Secondary outcome · Median, Days · Day 0 and Day 100

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1667.5 (Full Range 18 to 85)
BU,FLU, MEL + MGTA-456 Infusion233 (Full Range 0 to 66)

Secondary Graft Failure

Secondary outcome · Number, Percentage of participants · 2 Years

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1637.5
BU,FLU, MEL + MGTA-456 Infusion20

Platelet Recovery

Secondary outcome · Number, Percentage of participants · Day 42

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1656 (95% Confidence Interval 33 to 80)
BU,FLU, MEL + MGTA-456 Infusion250 (95% Confidence Interval 1 to 99)

Treatment Related Mortality (TRM)

Secondary outcome · Number, Percentage of participants · 6 Months

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion166 (95% Confidence Interval 0 to 18)
BU,FLU, MEL + MGTA-456 Infusion250 (95% Confidence Interval 15 to 85)

Grades II-IV Acute GVHD

Secondary outcome · Number, Percentage of participants · Day 100

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1625 (95% Confidence Interval 4 to 46)
BU,FLU, MEL + MGTA-456 Infusion20 (95% Confidence Interval 0 to 100)

Grades III-IV Acute GVHD

Secondary outcome · Number, Percentage of participants · Day 100

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1619 (95% Confidence Interval 0 to 37)
BU,FLU, MEL + MGTA-456 Infusion20 (95% Confidence Interval 0 to 100)

Chronic GVHD

Secondary outcome · Number, Percentage of participants · 1 Year

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1613 (95% Confidence Interval 0 to 28)
BU,FLU, MEL + MGTA-456 Infusion20 (95% Confidence Interval 0 to 100)

Relapse

Secondary outcome · Number, Percentage of participants · 2 Years

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1625 (95% Confidence Interval 4 to 46)
BU,FLU, MEL + MGTA-456 Infusion250 (95% Confidence Interval 1 to 99)

Non-catheter Associated Bacterial Infections

Secondary outcome · Number, Percentage of participants · Day 100

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion166
BU,FLU, MEL + MGTA-456 Infusion20

Overall Survival (OS)

Secondary outcome · Number, Percentage of participants · 2 Years

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1669
BU,FLU, MEL + MGTA-456 Infusion20

Event-Free Survival (EFS)

Secondary outcome · Number, Percentage of participants · 2 Years

GroupAnalysedValue
FLU, CY, TBI + MGTA-456 Infusion1669
BU,FLU, MEL + MGTA-456 Infusion20

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.